pharmaphorum11h
Amgen picks up key colorectal cancer okay for KRAS drug
The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...
pharmaphorum11h
AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year
Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a mixed bag. But headwinds, like tariffs and drug pricing, are clearly blowing ...
The Pharma Letter16h
FDA greenlight for AstraZeneca’s Datroway
UK pharma major AstraZeneca on Friday revealed that Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the ...
EuropaWire18h
AstraZeneca’s Calquence Gains U.S. Approval for First-Line Treatment of Mantle Cell Lymphoma, Following Positive Phase III Results
AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...
ジャパンタイムズ19h
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...